ufa slot game An online debate over foreign workers in tech shows tensions in Trump’s political coalitionSubsplash Acquires Pulpit AI, an Innovative Platform Leveraging AI to Help Streamline Content Creation & Boost Sermon Engagement for Churches

NYT ‘Connections’ Hints And Answers For Tuesday, December 3CINCINNATI (AP) — The Cincinnati Bengals have found all manner of ways to lose close games this season. Sunday's 44-38 loss to AFC North rival Pittsburgh can be blamed on a defense that missed tackles and allowed 520 yards of offense, and three turnovers by Joe Burrow. It's become a familiar story in this disappointing season. Cincinnati (4-8) keeps scoring lots of points but can't close out games. Seven of the Bengals’ eight losses this year have been by one score. Burrow has stopped talking about the possibility of going on a run and making the playoffs. He'd just like to win another game or two. “Playoffs are the furthest thing from my mind,” the fifth-year quarterback said. “You never know what can happen, so I’ll keep putting one foot in front of the other and try to be the best player I can be for the rest of the season, week in and week out.” The Bengals allowed Steelers quarterback Russell Wilson to throw for a season-high 414 yards and three touchdowns. After Wilson threw an interception that was returned for a touchdown, the Steelers (9-3) scored on seven of their last nine possessions. They didn't punt until early in the fourth quarter. Burrow lost two fumbles and threw an interception. “We haven’t done enough to earn the win,” coach Zac Taylor said. “It’s a simple as that. It’s nobody else’s fault but our own. We haven’t earned it.” Turnovers aside, Burrow had another strong game, finishing with 28 for 38 for 309 yards with three touchdowns. Burrow is having a great season statistically, and he hasn't hidden his disappointment and frustration about Cincinnati's narrow losses. ... WR Ja'Marr Chase had a touchdown catch to bring his league-leading total to 13. The defense missed tackles and couldn't hold off the Steelers, even with Burrow keeping the game close. It didn’t help that LB Logan Wilson (knee) and DT Sheldon Rankins (illness) had to sit out. The Bengals have allowed 34 or more points six times, including in four of the past five games. Cincinnati became the first NFL team to lose four games in a season in which it scored 33 points or more. RB Chase Brown has been dependable as the featured back since Zack Moss went down with a neck injury. He rushed for 70 yards and a touchdown against the Steelers. He also had three catches for 30 yards. The second-year back has 677 yards rushing and six TDs. “He’s really coming along, improving his game every single week,” Burrow said. “Pass game, run game, running hard, understanding his protection responsibilities. He’s a guy that practices hard, plays hard, and a guy you can count on.” The Bengals' coaching staff. Something has got to give. There was no excuse for the defense to play this badly after a bye week. The unit gave up 500-plus yards for the second time this season. None were reported in the game. 30.3 — The average points per game by the Bengals against teams with a .500 or better record this season. They are 0-7 in those games. The Bengals will try to regroup before facing the Dallas Cowboys (5-7) next Monday night. AP NFL: https://apnews.com/hub/NFLMETAIRIE, La. (AP) — Dejounte Murray plans to return to the New Orleans Pelicans ' lineup on Wednesday night for the first time since fracturing his left hand in a season-opening victory over Chicago on Oct. 23. And when Murray takes the court against the Toronto Raptors , his mother will be on his mind. After practice on Tuesday, Murray discussed his impending return and disclosed more details about the previously unspecified “personal matters” that caused him to leave the team during the final days of the preseason. His mother had a stroke, he said. “It was tough to leave and go deal with that. As she got better, she wanted me to come play,” Murray said of his last-minute decision to start against Chicago. He added that his hand injury near the end of that game was God's way of telling him, “‘Nah, you need to stay with your mom.’” “I was more concerned about my mother. That was my priority,” Murray continued. “I wasn’t really worried about my recovery.” Murray's mother has recovered well, he said, while he is “healthy and ready to help this team.” “I’m ready to hoop. Play for my mother — she’s going to be watching," Murray said. “I’m ready to compete, bring that winning spirit.” The Pelicans (4-14) certainly could use the help, having lost 14 of 16 games since opening the season with a pair of victories. Injuries have ravaged the roster. At times, all five starters have been out. Star power forward Zion Williamson has missed 12 games this season — one with an illness and 11 with a hamstring injury. Herb Jones has been sidelined by a shoulder strain and Brandon Ingram's status is in doubt after he sat out practice on Tuesday with calf soreness that also sidelined him during a loss on Monday night at Indiana. But at least two starters — Murray and fellow guard CJ McCollum — are expected to play against the Raptors. “I don’t care how many games we’ve lost. I just know every time I step on the floor I feel like we can win games,” said Murray, who had 14 points, 10 assists and eight rebounds in his lone game with the Pelicans. "That’s just my mentality, and I feel like it can carry over to a lot of guys.” AP NBA: https://apnews.com/hub/NBA

WASHINGTON (AP) — A ninth U.S. telecoms firm has been confirmed to have been hacked as part of a that gave officials in access to private texts and phone conversations of an unknown number of Americans, a top White House official said Friday. Biden administration officials said , as well as dozens of nations, had been affected by the Chinese hacking blitz known as Salt Typhoon. But deputy national security adviser Anne Neuberger told reporters Friday that a ninth victim had been identified after the administration released guidance to companies about how to hunt for Chinese culprits in their networks. The update from Neuberger is the latest development in a massive hacking operation that has alarmed national security officials, exposed cybersecurity vulnerabilities in the private sector and laid bare China’s hacking sophistication. The hackers compromised the networks of telecommunications companies to obtain customer call records and gain access to the private communications of what officials have said is a a limited number of individuals. Though the FBI has not publicly identified any of the victims, officials believe senior U.S. government officials and prominent political figures are among those whose whose communications were accessed. Neuberger said Friday that officials did not yet have a precise sense how many Americans overall were affected by Salt Typhoon, in part because the Chinese were careful about their techniques, but that a “large number” were in the Washington-Virginia area. Officials believe the goal of the hackers was to identify who owned the phones and, if they were “government targets of interest,” spy on their texts and phone calls, she said. The FBI said most of the people targeted by the hackers are “primarily involved in government or political activity.” Neuberger said the episode highlighted the need for required cybersecurity practices in the telecommunications industry, something the Federal Communications Commission is to take up at a meeting next month. In addition, she said, the government was planning additional actions in coming weeks in response to the hacking campaign, though she did not say what they were. “We know that voluntary cyber security practices are inadequate to protect against China, Russia and Iran hacking of our critical infrastructure,” she said. The Chinese government has denied responsibility for the hacking. Eric Tucker, The Associated Press

New I’m a Celebrity ‘feud’ as Barry McGuigan snaps at campmate amid ‘tension’ off-screenA senior Taliban leader in Afghanistan has indicated that they will continue to provide refuge to anti-Pakistan militants, describing them as "guests" under the country's traditions. Taliban Information Minister Khairullah Khairkhwa made the rare remarks just days after the Pakistani military reportedly conducted airstrikes against suspected terrorist locations in an eastern Afghan border province. The Taliban claimed that Tuesday's attack in Paktika resulted in the deaths of nearly 50 civilians, predominantly refugees from Pakistan. While the claims could not be verified from independent sources, the United Nations said that it had "received credible reports" from the remote Afghan province that dozens of civilians, including women and children, were killed in the Pakistani airstrikes. Islamabad has refrained from publicly acknowledging the cross-border strikes, but Pakistani security officials anonymously confirmed and told reporters that the military action had targeted and destroyed several "terrorist hideouts" of the Tehrik-e-Taliban Pakistan (TTP), an outlawed group engaged in lethal attacks against Pakistan. Several key TTP commanders were also said to be among more than a dozen militants killed. "We must honor the Afghan nation's commitment to safeguarding these guests, friends," an angry Khairkhwa said while denouncing the Pakistani attack. He was apparently referring to the TTP in his speech aired by Taliban-controlled state television and shared via X social media platform Friday. The Taliban minister emphasized the need for Pakistan "to draw lessons from the consequences of military interventions" in Afghanistan by Britain, the former Soviet Union and the United States, respectively, since the 19th century. "Anyone who attacks Afghanistan or harbors such intentions must learn from the defeat of three superpowers," Khairkhwa asserted. This is the first public admission by a senior Taliban leader regarding the presence of TTP operatives in the country. Previously, Taliban officials have vehemently denied their existence, claiming that no foreign militants are permitted to operate and pose a threat to other nations from Afghan soil. TTP, designated as a global terrorist organization by the United Nations, has escalated attacks in Pakistan since the Taliban's August 2021 resurgence to power in Kabul, killing hundreds of Pakistani civilians and security personnel. On Friday, Pakistani Prime Minister Shehbaz Sharif expressed his government's intention to enhance economic and trade relations with Afghanistan. However, he stated that the threat of TTP-led cross-border terrorism impedes that progress. "Unfortunately, the TTP continues to operate from there and killing innocent people inside Pakistan. This cannot go on," Sharif said in his televised remarks to a Cabinet meeting in Islamabad. "They must rein in TTP. ... This constitutes a red line for us. The TTP operating from Afghan soil is unacceptable under any circumstances," he stressed. Sharif said his country was ready to talk with the Afghan government to address the issue. "But there can be no progress if, on the one hand, they seek to foster relations with Pakistan while simultaneously permitting TTP to operate with impunity," he emphasized. Separately, the Pakistani military reported Friday that its counterterrorism operations and clashes with TTP militants resulted in the killings of over 900 "terrorists" this year, including 27 Afghan suicide bombers and fighters. The violence also left nearly 400 Pakistani security forces and officers dead, said Lieutenant General Ahmed Sharif Chaudhry, the military spokesperson. Who is Khairkhwa? Khairkhwa, a U.N.-sanctioned Taliban leader, was captured by U.S. forces in collaboration with Pakistani counterparts in early 2002 and subsequently transferred to the U.S. Guantanamo Bay prison center. He was freed along with four other senior Taliban leaders in 2014 as part of a Qatar-mediated exchange for the release of U.S. soldier Sgt. Bowe Bergdahl. Following the Sept. 11, 2001, terrorist attacks on the United States, American and Western-allied forces invaded Afghanistan, overthrowing the then-Taliban government due to its refusal to surrender Osama bin Laden, the leader of al-Qaida, who was accused of orchestrating the deadly attacks from his Afghan bases. The Taliban leadership at the time justified its refusal to surrender bin Laden, asserting that he was a "guest" in the country and that surrendering him would violate local traditions. Subsequently, the Taliban regrouped and launched an insurgency against U.S.-led foreign forces, using sanctuaries on Pakistani soil. Bin Laden evaded capture and fled to Pakistan, where he was eventually tracked down and killed by American troops in 2011. Taliban leaders pledged to combat transnational militant networks to prevent them from using Afghanistan as a haven for global attacks after they seized power three years ago. However, an annual U.S. terrorism report released earlier this month cast doubts on Taliban counterterrorism commitments, citing TTP's growing attacks against Pakistan from Afghan sanctuaries and the threat transnational groups pose to regional stability from Afghanistan.

New pictures of Feroze Khan and his wife dispel rumours of separation

THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE Amgen